SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI CRYPTO is trending amid community excitement, with many highlighting bullish technical patterns and anticipating a potential CoinMarketCap (CMC) listing. Discussions revolve around the strong community and the token's potential within the Solana ecosystem. Some users express concerns about potential pump-and-dump schemes.

Aventus Network

Aventus Network ($AVT) is trending as community members discuss its chart setup and potential for a breakout, noting real-world partnerships and Polkadot integration. Traders are watching volume closely, while also discussing potential catalysts such as a new proposal. The community is speculating on future price targets.

Linea is the Layer 2 built from first principles to strengthen Ethereum and the entire ETH economy. Every aspect of its design—from its productive ETH burn mechanics, and capital efficient native yield, to its underlying Ethereum-equivalent zk tech—amplifies the value and utility of Ethereum Mainnet. All of this is backed by the largest ecosystem fund in the space, managed by the most trusted Ethereum builders. With institutional-grade infrastructure, and deep integration across DeFi, Linea is the best chain for ETH capital, where every transaction and every block strengthens Ethereum. Linea is where Ethereum wins.

Linea

Linea is trending amid discussions about its potential use by the SWIFT network, with community members analyzing its implications for the Ethereum ecosystem and traditional finance. Some are speculating on Linea's growth potential and comparing it to competitors, while others are discussing its underlying technology and recent performance metrics. The community is also weighing the potential impact of key figures associated with Linea.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network ($REACT) is trending amidst community discussions about its potential, particularly after its integration with Abstract Chain and Shogun, enabling cross-chain triggers and on-chain AI automation. Some community members are speculating about future Coinbase listings and anticipating a price surge, while others debate potential price drops and the influence of certain traders. The migration away from $PRQ and its impact on the token's price is also a hot topic.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending as the community debates its future, with some expressing concerns about past project failures within the ecosystem and a lack of automated burns, while others remain hopeful and discuss potential opportunities with SHIB on BASE. Community members are also comparing SHIB to other meme coins and discussing the potential for an altcoin season, while some traders express frustration with SHIB's price action.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph ($HBAR) is trending amid discussion of potential ETF filings and its underlying technology. Community members are weighing the potential impact of institutional adoption and comparing HBAR's performance against other cryptocurrencies like XRP and XLM, while others express frustration over its price action relative to meme coins.

Green Satoshi Token

Green Satoshi Token is trending as the community anticipates a potential pump, fueled by increased volume and technical indicators suggesting a possible breakout. Many are pointing to its low market cap and historical price movements, expressing belief that GSTSOL is coiling up for a significant run, reminiscent of its past performance. Some users are also referencing its association with the STEPN app.

Hege is on a quest to become a successful meme in order to win the heart of his crush, Hegena.  Join the $HEGE-fund to help turn Hege's dream into reality!  The Hege story features 10 chapters, that are unlocked at various market cap goals, ranging from $1m-$1b.  NFT's, airdrops, rewards and more are also unlocked at the release of every chapter!  Hege is on a quest to become a successful meme in order to win the heart of his crush, Hegena.  Join the $HEGE-fund to help turn Hege's dream into reality!  The Hege story features 10 chapters, that are unlocked at various market cap goals, ranging from $1m-$1b.  NFT's, airdrops, rewards and more are also unlocked at the release of every chapter!

Hege

Hege is trending as the community eagerly awaits a major announcement regarding upcoming marketing plans and CEX listings, fueling excitement around the project's potential. Community members express strong conviction in Hege's long-term vision and unique brand, emphasizing its active community and innovative approach within the Solana meme space. With growing anticipation for the reveal, the community is rallying behind Hege, reinforcing its position as a top contender among Solana brandcoins.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is experiencing increased attention, potentially mirroring the movements of Zcash, with community members pointing to Elliott Wave analysis suggesting a possible retracement toward the $44-$50 range.  Discussions revolve around its ability to hold gains and comparisons to other cryptocurrencies, with some users anticipating a significant pump. Additionally, recent partnerships and integrations, like the one with Vultisig, are being highlighted as potential catalysts.

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.

DiaMedica Therapeutics Inc

DiaMedica Therapeutics ($DMAC) is trending due to community discussion around its drug, rinvecalinase, and its potential in treating acute ischemic stroke and pre-eclampsia, following promising preliminary data. The community is actively discussing insider buying activity, a recent HC Wainwright & Co. rating update to Buy with a $12 target, and upcoming catalysts, viewing it as a high-risk, high-reward play with a potentially significant impact on unmet medical needs. Mentions of Leon Cooperman highlighting DMAC as a value play on CNBC have also sparked interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Avidity Biosciences, Inc. (RNA) fell 20% in the pre-market session on Thursday after the company announced that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/avidity-biosciences-announces-proposed-public-offering-of-common-stock-302553124.html">stated</a> that it intends to grant the underwriters an option to purchase up to an additional $75 million of shares, while adding that there can be no assurance as to whether or when the offering may be completed.The proceeds of the offering are expected to advance the development of the company’s three late-stage clinical programs, help build appropriate commercial inventory levels to support multiple potential launches, and expand its commercial infrastructure. The company also intends to progress research and development associated with its Antibody Oligonucleotide Conjugates platform and use the proceeds for working capital and general corporate purposes.Avidity had cash, cash equivalents, and marketable securities totaling approximately $1.2 billion as of June 30. It had stated in August that it expects to have sufficient funds for its operations through mid-2027.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RNA">RNA stock</a> rose from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1360/122;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_7_16_45_AM_png_8af84254fb.webp" alt="RNA's Sentiment Meter and Message Volume as of 7:17 a.m. ET on Sept. 11, 2025 | Source: Stocktwits" width="1360" height="122"><figcaption>RNA's Sentiment Meter and Message Volume as of 7:17 a.m. ET on Sept. 11, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that Avidity stock has a good chance of hitting $100 in a year.<stembedurl>https://stocktwits.com/dgbio/message/628258214</stembedurl>The Financial Times <a href="https://stocktwits.com/news-articles/markets/equity/novartis-reportedly-eyeing-to-acquire-avidity-biosciences/chrSPptRd5k">reported</a> last month that Novartis made a takeover approach for Avidity, adding that the discussions were at an early stage and might not result in a deal.Avidity has three programs under development for three distinct rare diseases affecting the muscles: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne Muscular Dystrophy (DMD). Bank of America raised its price target on Avidity to $56 from $54 on Thursday, while maintaining a ‘Buy’ rating on the shares. The firm pinned the price target hike on recent study results, which showed that treatment with Avidity’s Del-zota reversed disease progression in patients with DMD.RNA stock is up by about 60% this year and by about 14% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-edge-higher-ahead-of-cpi-report/chwN03BRdv4">Dow Futures Edge Higher As Wall Street Awaits Consumer Inflation Data: ORCL, OPEN, KLAR, ADBE Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is Avidity Biosciences Stock Down 20% Pre-market Today?

Avidity said on Thursday that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.

Equity

Avidity said on Thursday that it intends to offer and sell $500 million of shares of its common stock in an underwritten public offering.


RNA Stock Moves More Than 30% in a Week: What's Driving This Rally?

Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.

Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates

Clene (CLNN) delivered earnings and revenue surprises of -59.18% and -73.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -8.80% and -58.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of +17.14% and +190.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of -13.79% and -9.64%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates

Arcutis Biotherapeutics (ARQT) delivered earnings and revenue surprises of +27.78% and +12.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Novartis AG (NVS) has made a takeover approach for San Diego-headquartered Avidity Biosciences (RNA), Financial Times <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/0e2c4788-141c-4dcf-9da9-1c3c6ab9dde1">reported</a> on Wednesday, citing people familiar with the matter.Novartis has been evaluating a bid for Avidity and expressed interest in an acquisition in recent weeks, the report said. The discussions are at an early stage and might not result in a deal, sources told FT.However, a takeover for Avidity would probably come with a premium, the people added.Shares of Avidity were trading 22% higher at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RNA">Avidity</a> trended in the ‘extremely bullish’ territory over the past 24 hours, coupled with ‘high’ message volume.<figure class="image"><img style="aspect-ratio:1252/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_06_at_12_23_34_PM_png_eab16d508a.webp" alt="RNA's Sentiment Meter and Message Volume as of 12:23 a.m. ET on Aug. 6, 2025 | Source: Stocktwits" width="1252" height="126"><figcaption>RNA's Sentiment Meter and Message Volume as of 12:23 a.m. ET on Aug. 6, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that they do not see the company management selling it for less than $70 or $80 per share, implying a significant premium to current price levels. &nbsp;<stembedurl>https://stocktwits.com/Atomickb/message/623958052</stembedurl>Meanwhile, retail sentiment around <a href="https://stocktwits.com/symbol/NVS">Novartis</a> jumped from ‘bearish’ to ‘neutral’ over 24 hours, accompanied by ‘normal’ levels of retail chatter.<figure class="image"><img style="aspect-ratio:1254/126;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_06_at_12_23_08_PM_png_0f5356da43.webp" alt="NVS's Sentiment Meter and Message Volume as of 12:23 a.m. ET on Aug. 6, 2025 | Source: Stocktwits" width="1254" height="126"><figcaption>NVS's Sentiment Meter and Message Volume as of 12:23 a.m. ET on Aug. 6, 2025 | Source: Stocktwits</figcaption></figure> Avidity has three programs under development for three distinct rare diseases affecting the muscles: myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne Muscular Dystrophy (DMD).Novartis, meanwhile, is looking to lose patent protection in the U.S. for some of its best-selling drugs, including heart failure drug Entresto and Xolair, used to treat several allergic conditions.In February, Novartis also agreed to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical company, for $925 million upfront.While NYSE-listed shares of Novartis are up by 17% this year, RNA stock soared 60%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/marco-rubio-swiss-president-discuss-39-tariffs-on-switzerland/chrScI0Rd5K">Marco Rubio, Swiss President Discuss 39% Tariffs On Switzerland</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis Reportedly Eyeing To Acquire Avidity Biosciences: But Retail Expects Management To Sell Only At Significant Premium

Novartis has been evaluating a bid for Avidity and expressed interest in an acquisition in recent weeks, FT reported.

Avidity, Dyne get Bernstein ratings as oligonucleotide muscle trials advance

Citi says SMid biotechs alternative to large caps as it starts coverage

Investing.com -- Citi has expanded its biopharmaceutical research coverage, initiating coverage on seven small- and mid-cap (SMid) biotechnology companies. Citi said SMid biotechs remain an attractive alternative to large-cap pharmaceutical firms, particularly amid healthcare policy uncertainties. Citi initiated coverage with Buy ratings on 89bio (NASDAQ:ETNB), price target $25. Apogee (NASDAQ:APOG), price target $95. Avidity, price target $70, BioNTech (NASDAQ:BNTX), price target $145. Kiniksa, price target $40. Kymera, price target $52

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

RNA
Avidity Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RNA News

RNA Avidity Biosciences Inc